• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up2.00% Nasdaq Up1.66%

    CorMedix, Inc. (CRMD)

    -NYSE MKT
    1.89 Up 0.27(16.67%) Feb 12, 4:02PM EST
    ProfileGet Profile for:
    CorMedix, Inc.
    1430 US Highway 206
    Suite 200
    Bridgewater, NJ 07921
    United States - Map
    Phone: 908-517-9500
    Website: http://www.cormedix.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:5

    Business Summary 

    CorMedix Inc., a pharmaceutical company, intends to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac, renal, and infectious diseases. The company markets Neutrolin, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, and central venous catheters used for vascular access in hemodialysis patients. Its product candidate is CRMD004, which is the gel formulation of Neutrolin intended for the treatment of wounds, skin infections, soft tissue infections, and the prevention of catheter exit site infections. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Bridgewater, New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on CorMedix, Inc.

    Corporate Governance 
    CorMedix, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 2; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Randy D. Milby MBA, 62
    Interim Chief Exec. Officer and Director
    287.00K0.00
    Dr. Antony E. Pfaffle M.D., 52
    Co-Founder, Vice Chairman, Chief Scientific Officer and Sec.
    266.00K0.00
    Mr. James R. Altland CPA, 67
    Interim Chief Financial Officer and Consultant
    N/AN/A
    Dr. William J. Vanjonack Ph.D.,
    VP of Technical Operations
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders